Williams S D, Donohue J P, Einhorn L H
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1573-6.
Nineteen patients with unresectable or metastatic urothelial cancer were treated with the combination of cis-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil. One patient died within 2 weeks of therapy and one patient had no measurable disease, leaving 18 patients evaluable for survival and toxicity and 17 patients evaluable for response. Eleven patients (65%) achieved a partial remission with attendant clinical improvement, with a median duration of 25 weeks. All nonresponders have died, with a median survival of 17 weeks. The median survival of responding patients was 40 weeks, with two patients alive at 33+ and 63+ weeks. Of particular interest are three patients who had resections of residual pelvic disease after significant regression with chemotherapy. One of these patients remains disease-free at 63+ weeks. Toxicity was significant but generally manageable.
19例无法切除或转移性尿路上皮癌患者接受了顺式二氯二氨铂（II）、阿霉素和5-氟尿嘧啶联合治疗。1例患者在治疗2周内死亡，1例患者无可测量疾病，剩余18例患者可评估生存情况和毒性，17例患者可评估反应。11例患者（65%）获得部分缓解并伴有临床改善，中位缓解持续时间为25周。所有未缓解患者均已死亡，中位生存期为17周。缓解患者的中位生存期为40周，2例患者分别在33 +周和63 +周时仍存活。特别值得关注的是3例患者，他们在化疗后病情显著消退，随后对残留盆腔疾病进行了切除。其中1例患者在63 +周时仍无疾病。毒性显著但总体可控。
